Skip to content

Evaluating the Use of a Concentrated Surfactant Gel in Burn Patients

Evaluating the Use of a Concentrated Surfactant Gel in Burn Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04084093
Enrollment
0
Registered
2019-09-10
Start date
2020-02-12
Completion date
2020-04-08
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Brief summary

This will be an observational study evaluating subject's perception of pain to dressing changes during removal and application of a surfactant gel. Wound healing will also be monitored. Anxiety before dressing change will be measured using a burn specific pain anxiety scale. Study intervention will include cleansing the wound per the facility's standard of care, followed by applying the investigational product on the wound. This will be followed by placing an appropriate secondary dressing.

Interventions

DEVICESurfactant Gel

This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.

Sponsors

Medline Industries
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject should be an inpatient, per the Two-Midnight rule at the time of study initiation. * At the time of subject's admission in the hospital, duration of his or her burn wound should be \< or equal to 24 hours. * Subject who has a partial thickness burn wound, or an indeterminate burn wound, or who has both these characteristics in the same wound, as determined by the site Principal Investigator. * Subject's wound included in this study, does not require any surgical intervention. * Subject is able and willing to comply with requirements of this trial protocol. * Voluntarily signed informed consent obtained before any trial-related procedures are performed. * Subject must be able to communicate effectively with study personnel. * Subject has burn total body surface area (TBSA) between 1-20%.

Exclusion criteria

* Subjects with electrical or radiation burns. * Subjects who are pregnant, nursing or planning to become pregnant during the course of the study. * Subjects who have known allergies to any ingredients in the dressings used in the study. * Subjects taking opiates during the study duration. * Subjects with an active diagnosis of substance use disorder within the past six months. * Subjects with previously diagnosed issues with pain perception, including conditions such as peripheral neuropathy, if they will preclude accurate assessment of primary and secondary endpoints. * Subjects with an active infection prior to enrollment. * Subject has previous or current systemic disease(s) which, in the judgement of the investigator, is likely to interfere with treatment. Subjects with well-controlled diabetes mellitus (HbA1C\<8.5) shall be permitted.

Design outcomes

Primary

MeasureTime frameDescription
Self-reported evaluation of subject pain perception during dressing changes using a numerical pain scale.Baseline to Day 30The numerical pain scale will be from 0 to 10 with 0 being no pain at all and 10 being the worst pain ever possible. This is the numeric rating scale.

Secondary

MeasureTime frameDescription
Measure percent change in epithelium as recorded by the clinician.Baseline to Day 30
Measure percent change in necrotic tissue in the wound bedBaseline to Day 30
Measure change in wound sizeBaseline to Day 30
Measure anxiety using a burn specific anxiety scaleBaseline to Day 30A burn-specific pain anxiety scale will be used to measure level of anxiety. Items will be scored on a 100mm visual analog line with two reference points, 0 and 100. These reference points will also be identified by expressions not at all and the worst imaginable way. Subjects will be requested to scale the strength of their feelings relative to two reference points.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026